GET DAILY SIGNALSWhy Is PepGen (PEPG) Stock Up +22.99% Today?
Key Takeaways
- PEPG shares climbed roughly 23% in Wednesday's session, extending a powerful rally that began after Tuesday's Phase 2 data release.
- The move follows positive top-line results from the FREEDOM2-DM1 trial of PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
- Wall Street responded with price-target increases, including Craig-Hallum raising its target to $16 from $11.
- A proposed $125 million public offering, announced Tuesday evening, added a capital-markets layer to the story.
- Trading volume remained exceptionally heavy relative to the company's historical average.
- Investors are now watching the 12.5 mg/kg cohort data expected in the first half of 2027.
- For more detail on this stock, explore its Price Targets, Earnings, and Forecast pages.
- Interested in automated strategies? Explore Tickeron's Trending AI Robots.
Opening Summary
PepGen Inc. (PEPG), a clinical-stage biotechnology company pioneering oligonucleotide therapies for rare genetic diseases, extended its rally on Wednesday. Shares traded up approximately 22.99% at $5.67, building on a prior-session close of $4.61. The advance reflects continued buying momentum in the wake of positive Phase 2 clinical data, reinforced by fresh analyst price-target increases and the announcement of a proposed capital raise.
Catalyst: Positive Phase 2 FREEDOM2-DM1 Data
The primary driver behind PEPG's move is the positive top-line data from the Phase 2 FREEDOM2-DM1 study of PGN-EDODM1, an investigational treatment for myotonic dystrophy type 1 (DM1), a rare, progressive genetic muscle disorder. The company reported a mean muscle splicing correction of 46.5% at Week 13 for the 10 mg/kg dose, versus roughly 6.8% in the pooled placebo arm, with five of six treated patients exceeding 20% correction and four surpassing 50%.
Investigators also documented functional gains, including an improvement of approximately 3.9 seconds in Video Hand Opening Time, a measure of myotonia, alongside gains in hand grip strength, ambulation, and mobility. The 10 mg/kg dose was generally well tolerated, with no severe adverse events or treatment discontinuations. The results represent the highest level of splicing correction reported in a multiple-dose DM1 study, strengthening confidence in the company's broader Enhanced Delivery Oligonucleotide (EDO) platform.
Analyst Price-Target Raises
The clinical readout triggered a wave of constructive commentary from the sell side. Craig-Hallum raised its price target on PEPG to $16 from $11 while maintaining a Buy rating, citing the positive 10 mg/kg data. H.C. Wainwright reiterated a Buy rating with a $20 price target. Analysts highlighted the drug's competitive positioning in the DM1 space and the potential for further re-rating tied to sustained functional benefit, long-term safety, and the upcoming 12.5 mg/kg cohort results.
Proposed $125 Million Public Offering
Adding to the day's news flow, PepGen announced a proposed public offering of $125 million in common stock and, for certain investors, pre-funded warrants, with a 30-day underwriter option for up to an additional $18.75 million. The company intends to use the net proceeds to fund ongoing clinical development of PGN-EDODM1 and for general corporate purposes. While share offerings can create near-term dilution concerns, the raise was viewed in the context of a sharply higher share price and a strengthening clinical data package.
Market Context and Trading Activity
Trading activity in PEPG has been exceptionally elevated since the data release. Tuesday's session saw tens of millions of shares change hands, far above the company's three-month average daily volume of roughly one million shares, and Wednesday's follow-through continued at well-above-normal levels. The rally has also unfolded against a competitive backdrop in neuromuscular disease, where investors are weighing DYN's advancing DM1 program and a recent Phase 3 setback reported by NVS for an acquired DM1 candidate — dynamics that have sharpened attention on PepGen's differentiated splicing-correction approach.
What Comes Next for PEPG
Looking ahead, investors are focused on several near- and medium-term catalysts for PEPG. The company expects results from its fully enrolled 12.5 mg/kg cohort in the first half of 2027, along with open-label extension data planned for January 2027. Additional interim data from other studies is also expected in 2027. Key uncertainties include the ongoing partial clinical hold in the United States, the regulatory and registrational path forward, and the durability of functional benefits and long-term safety observed in the trial. As with all clinical-stage biotechnology companies, binary clinical and regulatory outcomes remain a core risk.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies. Tickeron offers hundreds of AI-driven trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. These bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving investors a way to monitor algorithmic approaches to the market. Explore the Trending AI Robots to see which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PEPG's RSI Oscillator penetrates overbought territory
The RSI Indicator for PEPG moved into overbought territory on November 10, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PEPG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
PEPG broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 59 cases where PEPG's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 10, 2026. You may want to consider a long position or call options on PEPG as a result. In 77 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 89%.
The Moving Average Convergence Divergence (MACD) for PEPG just turned positive on November 10, 2026. Looking at past instances where PEPG's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.
PEPG moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 198 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Aroon Indicator entered an Uptrend today. In 102 of 112 cases where PEPG Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.431) is normal, around the industry mean (3.498). P/E Ratio (-2.470) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement